Penny Inventory Lexicon Prescribed drugs Surges On Weight problems Pact Price $1 Billion With Novo Nordisk – Lexicon Prescribed drugs (NASDAQ:LXRX), Novo Nordisk (NYSE:NVO)

Lexicon Prescribed drugs Inc. LXRX inventory is buying and selling greater on Friday.

Penny inventory Lexicon Prescribed drugs entered into an unique license settlement with Novo Nordisk A/S NVO on Friday for LX9851, a first-in-class, oral non-incretin improvement candidate in weight problems and related metabolic issues.

Underneath the phrases of the settlement, Novo Nordisk obtains an unique, worldwide license to develop, manufacture, and commercialize LX9851 in all indications.

Additionally Learn: Lexicon Prescribed drugs (LXRX) Inventory Is Down: What’s Going On?

Lexicon will likely be chargeable for finishing the agreed-upon Investigational New Drug (IND) application-enabling actions for LX9851.

Novo Nordisk will file the IND and all additional improvement, manufacturing, and commercialization of LX9851.

Lexicon is eligible to obtain upfront and near-term milestone funds of as much as $75 million. In whole, Lexicon will likely be eligible to obtain $1 billion in upfront and potential improvement, regulatory and gross sales milestone funds. Lexicon can be entitled to tiered royalties on web gross sales of LX9851.

LX9851, found and developed by Lexicon, is a potent and selective oral small molecule inhibitor of Acyl-CoA Synthetase 5 (ACSL5)​.

ACSL5 performs a key function within the metabolic pathway, which regulates fats accumulation and power steadiness.

Moreover, LX9851 could activate the ileal brake mechanism resulting in elevated satiety by delaying gastric emptying and suppressing urge for food. Preclinical in vivo efficacy knowledge introduced at Obesity Week 2024 present that LX9851, when mixed with Novo Nordisk’s semaglutide, considerably decreased weight, meals consumption and fats mass in comparison with semaglutide alone.

Individually, LX9851 mitigated weight regain and had optimistic results on liver steatosis when launched after semaglutide discontinuation.

Value Motion: LXRX inventory is up 97.4% at $0.69 throughout the premarket session on the final verify Friday.

Learn Subsequent:

Photograph: Shutterstock